Skip to main content

Table 3 Intensive care and surgical management during the study period

From: Congenital diaphragmatic hernia presenting with symptoms within the first day of life; outcomes from a non-ECMO centre in Denmark

Management/TreatmentAll CDH casesSurvivorsNon-survivors
Mechanical ventilation92 (97%)71 (96%)21 (100%)
HFO75 (79%)56 (76%)19 (90%)
iNO36 (38%)18 (24%)18 (86%)
Magnesium, iv14 (15%)6 (8%)8 (38%)
Sildenafil, ga13 (14%)6 (8%)7 (33%)
Surfactant13 (14%)5 (7%)8 (38%)
Vasoactive drugs60 (63%)39 (53%)21 (100%)
Nor-epinephrine15 (16%)6 (8%)9 (43%)
Dopamine51 (54%)34 (46%)17 (81%)
Dobutamine16 (17%)9 (12%)7 (33%)
Milrinone14 (15%)5 (7%)9 (43%)
Epinephrine12 (13%)1 (1%)11 (52%)
Sedatives80 (84%)59 (80%)21 (100%)
Fentanyl77 (81%)57 (77%)20 (95%)
Midazolam54 (57%)39 (53%)18 (86%)
Methadone11 (12%)11 (15%)0 (0%)
Phenobarbital43 (45%)37 (50%)6 (29%)
Clonidine10 (11%)9 (12%)1 (5%)
Operation84 (88%)74 (100%)10 (48%)
Patch repair (operation)17 (20%)12 (16%)5 (50%)
Recurrent hernia (operation)8 (8%)7 (10%)1 (1%)
  1. Data are presented as percentages. iv intravenous, ga gastrointestinal